Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Status:
Completed
Trial end date:
2018-02-26
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25
and 50 mg) compared to placebo for the acute treatment of a single migraine attack.